share_log

Allogene Therapeutics To Present Phase 1 Data On ALLO-316 For Advanced CD70 Positive Renal Cell Carcinoma At IKCS And SITC Meetings; FDA Grants RMAT Designation For Potential Single-Infusion AlloCAR T Treatment

Allogene Therapeutics To Present Phase 1 Data On ALLO-316 For Advanced CD70 Positive Renal Cell Carcinoma At IKCS And SITC Meetings; FDA Grants RMAT Designation For Potential Single-Infusion AlloCAR T Treatment

allogene therapeutics將在IKCS和海豐國際會議上就ALLO-316用於愛文思控股70陽性腎細胞癌的1期數據進行報告; FDA授予RMAt注射用抗原特異性載體單次輸注用於潛在治療
Benzinga ·  2024/11/05 22:11

Allogene Therapeutics To Present Phase 1 Data On ALLO-316 For Advanced CD70 Positive Renal Cell Carcinoma At IKCS And SITC Meetings; FDA Grants RMAT Designation For Potential Single-Infusion AlloCAR T Treatment

allogene therapeutics將在IKCS和海豐國際會議上發佈ALLO-316用於愛文思控股CD70陽性腎細胞癌的1期數據;FDA授予RMAt標誌潛在單次注射AlloCAR t治療

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論